Mylan

942 articles with Mylan

• Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission

  9/27/2019

  Mylan N.V. announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission.

• Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India

  9/25/2019

  Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris

• Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris

  9/20/2019

  Entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.

• Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer

  9/17/2019

  Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used to treat certain types of advanced breast cancer in women who have experienced menopause as monotherapy and in advanced or metastatic breast cancer in combination with other products.

• 

  Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

  8/30/2019

  The U.S. Food and Drug Administration (FDA) gave tentative approval to Mylan’s pemetrexed, a generic version of Eli Lilly’s $2 billion lung cancer drug, Alimta.
• 

  Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

  8/22/2019

  Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan. The suit is an attempt to block Mylan from marketing a generic version of Novo Nordisk’s diabetes drug Victoza.

• SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

  7/30/2019

  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.V. in connection with the proposed acquisition of the Company by Pfizer Inc..

• Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT

  7/29/2019

  Pfizer’s second-quarter 2019 earnings conference call with investment analysts has been rescheduled for, July 29, 2019, at 10:30 a.m. EDT.

• Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer

  7/29/2019

  Mylan's Board of Directors shared the following statement regarding Heather Bresch's retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division of Pfizer.

• Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine

  7/29/2019

  Combines Mylan’s sustainable, diverse and differentiated portfolio of medicines with Upjohn’s trusted, iconic brands

• Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine

  7/29/2019

  Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.

• Mylan Reports Second Quarter 2019 Results

  7/29/2019

  Mylan N.V. announced its financial results for the three and six months ended June 30, 2019.

• 

  Mylan's Merger with Pfizer's Off-Patent Drug Unit Will Create 'New Champion for Global Health'

  7/29/2019

  The new company will be helmed by Mylan's Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.

• Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories - June 14, 2019

  6/14/2019

  First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients   [14-June-2019]   DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (

• Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories

  6/14/2019

  First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients   [14-June-2019]   DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (

• Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference - May 20, 2019

  5/20/2019

  Theravance Biopharma, Inc. and Mylan N.V. announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society International Conference in Dallas, Texas.

• Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

  5/20/2019

  Theravance Biopharma, Inc. and Mylan N.V. announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society International Conference in Dallas, Texas.

• Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic Society International Conference

  5/18/2019

  Global pharmaceutical company Mylan N.V. announced four scientific abstracts from the Wixela™ Inhub™ development program that will be presented at the 2019 American Thoracic Society International Conference in Dallas, May 17 – May 22.

• Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

  5/15/2019

  Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers   [15-May-2019]   HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , May 15, 2019 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced

• 

  Sandoz, Teva Vow to Fight Price-Fixing Allegations

  5/13/2019

  The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.